The Life Sciences team advised Arsenal Biosciences on the oversubscribed $325 million Series C funding round led by ARCH Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures (NVIDIA’s venture capital arm), Luma Group, funds and accounts advised by T. Rowe Price Associates, Inc., Rock Springs Capital, among others, with ongoing support from existing investors the Parker Institute for Cancer Immunotherapy (PICI), SoftBank Vision Fund 2, Bristol-Myers Squibb Company, Westlake Village BioPartners, Kleiner Perkins, Byers Capital, and Hitachi Ventures. The funding will go towards advancing ArsenalBio’s lead programs through development as the company continues to build its pipeline of therapeutic candidates for solid tumor cancers based on its proprietary T cell engineering technology, including logic gating. The funds will also drive further innovation in developing tools and processes for identifying new candidate cell therapies.
Arsenal Biosciences is a clinical stage programmable cell therapy company focusing on discovering and developing a pipeline of next-generation autologous T cell therapies to defeat cancer. The full-stack R&D engine is designed to generate multifunctional T cell medicines, enabled by precise and specific CRISPR- mediated insertion of large synthetic DNA cassettes. ArsenalBio is aiming to build the industry’s largest DNA library of potential therapeutic enhancing integrated circuits, incorporating logic gating for improved tumor targeting and synthetic features enabling multiple pharmaceutical functions. In pioneering a computationally driven approach alongside nonviral clinical manufacturing, they aim to deliver enhanced efficacy, increased patient safety, reduced stakeholder costs, and expanded market access.
The Goodwin team was led by Kevin Kabler, Lily Xu, and Mayim Wiens.
For more details on the funding, please read the press release, as well as coverage in Endpoint News.